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ABST RACT

Neuroendocrine breast carcinomas represent a rare subtype of breast
cancer. Their definition, prevalence and prognosis remain controversial
in the literature. Regarding the presentation, there are no differences
from other breast carcinomas and clinical syndromes related to hormone
production are extremely rare. Refinement of the classification of
neuroendocrine neoplasms of the breast is needed in order to improve
the reproducibility of their diagnostic criteria and to define their clinical
significance.
This article presents the case of a 44-year-old female patient diagnosed
with invasive breast carcinoma with neuroendocrine features, according
to the 2012 World Health Organization (WHO) definition, with focus on
presentation, clinical manifestations, diagnostic approach and
differential diagnosis.

Introduction
Carcinomas with neuroendocrine differentiation
represent <1% of breast carcinomas. However, since
neuroendocrine markers are not routinely used on breast
tumors with solid, alveolar and nested patterns of growth,
the true incidence is difficult to assess [1].
Since
primary
mammary
carcinoma
with
neuroendocrine features is rare, metastatic welldifferentiated neuroendocrine tumor (carcinoid) and poorly
differentiated neuroendocrine carcinoma/small cell
carcinoma should be excluded before making a final
diagnosis [1]. Metastases of the breast account for less than
1% of breast tumors and are most commonly hematologic
or metastases from the contralateral breast. Metastatic
neuroendocrine tumors account for 1-2% of breast
metastases [2].
There are two main theories on the histogenesis of
primary NETs of the breast. The first, a more controversial
theory, affirms that these tumors evolve from the
neoplastic transformation of native neuroendocrine cells.
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The second theory, which is more widely accepted, states
that neuroendocrine differentiation arises from divergent
differentiation of neoplastic stem cells into epithelial and
endocrine cell lines during early carcinogenesis [2].
This paper presents the case of a young woman,
diagnosed with invasive breast carcinoma with
neuroendocrine features, who had no major risk factors and
whose presentations were due to the presence of hepatic
metastases.

Case Presentation
Patient H.F., aged 44 years, female, presented with the
following complaints: pain in the right hypochondriac
region, asthenia, unintentional weight loss (approximately
13 kilos in four months), loss of appetite, nausea and
vomiting (2-3 episodes/day). She was referred to our
hospital by a regional hospital for further investigation and
biopsy of some hepatic lesions seen on an abdominal and
pelvic CT scans. At the CT scan, multiple hypodense
lesions in both hepatic lobes were described. In contrast-
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enhanced CT, the lesions appear as rapidly enhancing
lesions visible on the arterial phase. This enhancement
pattern is characteristic to hypervascular metastases such
as those from neuroendocrine tumors, renal cell carcinoma,
breast carcinoma, melanoma and thyroid carcinoma. In the
right lobe, the lesion had a maximum diameter of 176/111
mm AP/LL, while, in the left lobe, the maximum diameter
was up to 82 mm. There was also a small amount of ascites.
She had a history of tobacco use, but she had quit
smoking eleven years ago. The patient was also suffering
from arterial hypertension, for which she was under
treatment with angiotensin converting enzyme inhibitors
and diuretics. There was no relevant family history.
On the clinical examination, the patient was in a good
general state, apyretic, with a blood pressure of 130/70
mmHg, a pulse of 80 bpm, and a SpO2 of 98%. Lung and
cardiac auscultation revealed no pathological aspects and
the abdomen was insensitive to superficial and deep
palpation.
Laboratory investigation revealed: cholestasis with an
elevated alkaline phosphatase (ALP) of 472 U/l (98-279),
and a gamma-glutamyl transferase (GGT) of 305 U/l (732), thrombocytosis PLT 486x10^3/ul (150-350), elevated
erythrocyte sedimentation rate (ESR) 35 mm/1h (1-10).
The transaminases were within normal limits, the surface
antigen of the hepatitis B virus (HBsAg) was negative and
the antibodies to the hepatitis C virus (anti-HCV
antibodies) were also negative.
The presence of hepatic lesions was confirmed by
abdominal ultrasonography and a needle biopsy of the liver
was performed. Based on the clinical presentation,
ultrasound and CT scan images, the hepatic lesions were
suspected to be metastases, most probably, of a
neuroendocrine tumor.
In anticipation of the histological results, investigations
were conducted to search for a possible primary tumor. The
upper endoscopy revealed acute erythematous pangastritis,
while the lower endoscopy revealed grade II internal
hemorrhoids, but no tumors. A thoracic CT scan was also
performed, describing bone sclerotic lesions on the
vertebral bodies (T6, T10, T11), sternum, scapula bilateral
and the 6th left costal arch, and a mixed predominantly
osteolytic bone lesion on the 7th right costal arch. Besides
these bone lesions, a nodular densification in the right
breast was also observed.
A mammography (Figure 1) was performed, showing
an irregular opacity with spiculiform contour in the superoexternal dial of the right breast. The maximum diameter of
the lesion was 18/16 mm, and multiple microcalcifications
(over 30) were observed. The next step was the ultrasound
guided biopsy of the breast. At this moment, the possibility
of having two different tumors at the same time was also
included in the differential diagnosis.

Figure 1. Mammography of the right breast:
irregular opacity with spiculiform contour in the
supero-external dial with a maximum diameter of
18/16mm, and multiple microcalcifications.
The histopathological exam of the breast biopsy
(Figure 2), classified the breast lesion, according to the
WHO definition in 2012, as an invasive breast carcinoma
with neuroendocrine features. The coloration for neuron
specific enolase (NSE) and synaptophysin were positive,
while the cells were negative for chromogranin and CD56.
Moreover, estrogen receptors (ER) were present in 100%
of the tumor cells, while progesterone receptors (PR) were
80% positive. The ki67 index of proliferation was 5%. The
tumor was moderately differentiated, grade II Nottingham
with a total score of six (tubule formation=3, nuclear
pleomorphism=2, mitotic activity=1).

Figure 2. Breast biopsy. A. Hematoxylin and eosin
(HE) staining x20. Tumor cells are disposed in nests and
islands and no breast parenchyma is visible. The cells
are small, without visible cell boundaries, the
eosinophilic, fine granular cytoplasm is in small
quantities; nuclei with granular chromatin, and no
nucleolus visible; B. Immunohistochemical staining for
neuron-specific enolase (NSE). Tumor cells are positive
for NSE; C. Immunohistochemical staining for
ER, x20. All tumor cells are ER-positive. D.
Immunohistochemical staining for PR, x20. 80% of the
tumor cells are PR-positive
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The liver biopsy (Figure 3) confirmed the diagnosis by
describing the aspect of metastases originating most
probably from a mammary carcinoma. This was supported
by the presence of ER in the liver biopsy. Also, by
comparing the breast biopsy (Figure 2A) and the liver
biopsy (Figure 3A) in HE staining, it was observed that the
tumor cells were similar.

Figure 3. Liver biopsy – A) HE staining x20. A
fragment of liver parenchyma with tumor proliferation
formed by small and round cells with pale eosinophilic
cytoplasm and round nuclei with granular chromatin
and no nucleolus visible. The tumor cells are grouped
in nests and islands and are visible in the lower part of
the picture. B) Immunohistochemical staining for ER,
x20. Tumor cells are ER positive.
The final diagnosis was: Invasive breast carcinoma
with neuroendocrine features with liver and bone
metastases. Grade II hypertension with moderate to high
risk. Acute erythematous pangastritis. Grade II internal
hemorrhoids. The patient was referred to the oncologist.

Discussions
In this case, the patient was diagnosed with invasive
breast carcinoma with neuroendocrine features, according
to the WHO classification in 2012, based on the
immunohistochemical staining for NSE and the aspect of
tumor cells. The various definitions of this type of cancer
are worth being discussed, as there are few articles on this
topic, and the definitions have changed several times in the
last years, and this may affect the way these studies are
interpreted [3,4].
The lack of uniformity in the definition and
classification of neuroendocrine carcinomas hampers an
exact estimate of the prevalence of these tumors, ranging
from 0.1% to 15% depending on the series. This may also
explain the controversial data on the prognostic implication
of neuroendocrine differentiation in breast cancer [3]. In
2003, neuroendocrine carcinoma (NEC) of the breast was
endorsed as a distinct entity in the third edition of the WHO
Classification of Tumors series. Neuroendocrine tumors
(NETs) of the breast were defined as tumors of epithelial
origin, with morphology similar to that of gastrointestinal
and pulmonary NETs, expressing neuroendocrine
immunohistochemical
markers
(synaptophysin,
chromogranin A) in at least 50% of the total invasive tumor
cell population [4].
In 2012, in the fourth-edition volume WHO
classification of tumors of the breast, NECs were included
308

under the category “carcinomas with neuroendocrine
features”, and they were defined as tumors exhibiting
morphological features similar to those of the NETs of the
gastrointestinal tract and of the lung, expressing
neuroendocrine markers to any extent [4]. The revised
2012 WHO classification includes three categories of
NETs of the breast: (1) NETs well differentiated, which
resembles carcinoid tumors and includes low and
intermediate grade tumors; (2) NEC poorly differentiated
(small cell carcinoma), which has the same features as a
primary small cell carcinoma of the lung; (3) invasive
breast carcinoma with neuroendocrine features, including
no special type (NST), as well as special types such as solid
papillary carcinoma and the hypercellular subtype of
mucinous carcinoma [4-7].
Although the majority of the articles in the literature
refer to the definition from 2012, it is important to mention
that, in 2019, the International Agency for Research on
Cancer (IARC) and the WHO adopted the term
“neuroendocrine neoplasm (NEN)” as a term
encompassing all tumor classes with predominant
neuroendocrine differentiation, including both welldifferentiated and poorly differentiated forms. The
morphology and the expression of the markers of
neuroendocrine differentiation were recognized as the key
features defining these neoplasms at any specific
anatomical site. A uniform classification framework for
NENs at all anatomical locations was proposed in order to
reduce the inconsistencies and contradictions among the
various systems currently in use [4-7].
Regarding the clinical presentation, neuroendocrine
tumors of the breast occur predominately in white
postmenopausal women in the sixth to seventh decade of
life [2,5]. There are no notable or specific differences in
presentation from other high-grade breast carcinomas and
the clinical syndromes related to hormone production are
extremely rare. Serological tests may detect circulating
neuroendocrine markers such as chromogranin A [1,2].
"Carcinoid syndrome" is the term applied to a group of
symptoms mediated by various humoral factors elaborated
by some well-differentiated NETs which synthesize, store,
and release a variety of polypeptides, biogenic amines, and
prostaglandins. Carcinoid syndrome is most common in
the setting of disseminated disease, particularly liver
metastases, but it can occur in apparently locoregional
disease [8]. The liver inactivates bioactive products
secreted into the portal circulation. This may explain why
patients with gastrointestinal NETs most often develop
carcinoid syndrome if they suffer from hepatic metastases,
resulting in the secretion of tumor products into the
systemic circulation [9]. In the large majority of cases,
carcinoid syndrome is associated with metastatic tumors
originating in the midgut (jejunum, ileum, and cecum);
however, the expression is variable in individual patients.
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Less often, carcinoid syndrome is caused by a NET arising
in the lung or in the distal colon or rectum and extremely
rarely it is caused by NET arising in other sites such as the
breasts. In table 1, the most important clinical
manifestations of carcinoid syndrome are highlighted [10].
Table 1. Clinical manifestation of carcinoid syndrome
1. Cutaneous flushing - the typical flush associated with
midgut neuroendocrine tumors begins suddenly and
lasts from 30 seconds to 30 minutes. It primarily
involves the face, neck, and upper chest, which become
red to violaceous or purple, and it is associated with a
mild burning sensation.
2. Venous telangiectasia - appear late in the course of
carcinoid syndrome. They are due to prolonged
vasodilatation and most often occur on the nose, upper
lip, and malar areas.
3. Secretory diarrhea - stools may vary from few to
more than 30 per day, are typically watery and nonbloody, and can be explosive and accompanied by
abdominal cramping. Diarrhea is usually unrelated to
flushing episodes. Transit time through the intestine
may be extremely short.
4. Bronchospasm - wheezing and dyspnea, often during
flushing episodes. Carcinoid wheezing should not be
confused with bronchial asthma because treatment with
beta agonists can trigger intense, prolonged
vasodilation.
5. Cardiac valvular lesions - Carcinoid heart disease is
characterized by pathognomonic plaque-like deposits of
fibrous tissue. These deposits occur most commonly on
the endocardium of valvular cusps, the cardiac
chambers, and occasionally, the intima of the pulmonary
arteries or aorta. The valves and the endocardium of the
right side of the heart are most often affected because
the inactivation of humoral substances by the lung
protects the left heart. Left-sided valve disease may be
caused by right-to-left shunting or with high levels of
circulating vasoactive substances.
In this case, the presentation was also not specific and
was due mainly to pain in the right hypochondriac region,
caused by the infiltration of the liver. What is notable in
our case, is that the age of onset was 44 years and the
menopause was not installed.
The main risk factors for NEC of the breast are currently
believed to be the same as for non-neuroendocrine breast
cancer, such as age and family history. Moreover, the risk of
the disease may also be increased by early menarche, late
menopause as well as significant exposure to estrogen,
typical of patients undergoing hormone replacement therapy
or taking oral contraceptives [11]. Some evidence suggests
a link between high prolactin level and breast cancer
development; however, it is unclear whether breast NEC

may be associated with hyperprolactinemia. Zang et al.
have recently published two cases of breast NEC
associated with hyperprolactinemia, one patient suffering
from mental disorder under antipsychotic drugs, and
another one diagnosed in late pregnancy [12].
As well as the clinical presentation, the radiologic
characteristics are also unspecific and similar to the other
malignant breast lesions. In a mini review article, Gallo et
al. summarized the imaging characteristics of breast NEC,
reported in case reports or small series: the most common
mammographic appearance is a hyperdense, irregularly
shaped solitary mass; margins are more commonly
reported as indistinct, micro-lobulated or speculated. In
most cases, calcifications are absent [12-14]. Taking into
account the most common mammographic appearance
described by Gallo et al., it is important to remember that
multiple microcalcifications were observed in this case.
There are no data from prospective clinical trials on the
optimal management of NETs of the breast, and these
tumors are usually treated with the same strategy used for
other types of invasive breast carcinoma. Therefore,
outside of the context of the exceedingly rare NEC of the
breast, neuroendocrine differentiations in breast neoplasms
are not regarded as specific therapeutic implications [4].
Surgery is the mainstay of the treatment for early NEC of
the breast. Adjuvant radiation and systemic therapy must
be decided in a personalizing view. Regimens including
anthracyclines and/or taxanes are preferable when the
indication for chemotherapy exists. Also, patients with
positive hormone receptors are likely candidates for
adjuvant endocrine therapy [15].
Although breast NEC does not have a specific targeted
therapy, several new targeted therapies based on specific
biomarkers have recently been investigated in the NEC of
the lung and in other types of breast carcinomas, which may
provide guidance to their feasibility in breast NEC.
According to an analysis performed by S.Vranic et al.,
several potential targets for novel therapies in breast NEC
were identified, including farletuzumab and mirvetuximab
soravtansine (FOLR1), sacituzumab govitecan (TROP-2),
and HDAC inhibitors (H3K36Me3). For example, the
expression of TROP-2 protein was found in 21% of the
cases, suggesting that a small proportion of NEBCs may be
sensitive to target therapy with sacituzumab govitecan. In
some cases, CCND1 gene amplification may indicate the
usefulness of investigational therapies [16,17]. All currently
approved biomarkers of response to immune checkpoint
inhibitors, have proven negative so far, thus suggesting that
patients with neuroendocrine breast carcinoma are unlikely
to benefit from immunotherapy [18]. The reported results
should serve as an early indication of potential clinical
relevance in selected patients with breast NEC.
The tumor stage and the histological grade, which
encompass mitotic counts, are used as the main prognostic
309
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parameters. The prognostic relevance of neuroendocrine
differentiation in breast carcinoma is still under debate,
because of the lack of specific criteria for its definition;
therefore, several studies have been published with mixed
results [4]. These conflicting results might be explained by
the different inclusion criteria based on whether 2003 or
2012 WHO definitions were applied to identify NEC, by
the limited number of cases reported in each series and also
by the analysis performed considering NEC as a whole,
without analyzing the outcomes according to the different
histologic subtypes [19,20]. According to a study
published by Yang et al., within the same clinical stage or
grade, neuroendocrine tumors and neuroendocrine
carcinoma of the breast had worse disease-specific survival
(DSS) and overall survival (OS) than corresponding stage
or grade of invasive ductal carcinomas of no special type
(IDCs-NST). In univariate and multivariate survival
analyses, NENs of the breast had significantly worse DSS
and OS than IDCs-NST [21]. Even if this is a case of
advanced breast carcinoma, with liver and bone metastases
and a grade II Nottingham, the neuroendocrine component
of the tumor made it difficult to make statements about the
prognosis and the efficacy of the treatment.
A limitation of this case report is the lack of
information regarding the management of the case in the
oncology department and the response to the treatment. As
a strength point, this case report presents the discovery of
a rare tumor, in a young patient without other important
risk factors or comorbidities. It is worth mentioning that
one of the challenges of this case was its management, both
medically and with regard to the doctor-patient
relationship, because of the necessity to provide
information to the patient on a rare pathology whose
treatment and prognosis are not well known.

Conclusions
Neuroendocrine tumors of the breast are rare and they
can be misdiagnosed due to the lack of distinguishing
features on presentation and imaging. Also, the expression
of neuroendocrine markers is probably under-recognized
in breast cancer, because routine staining of invasive breast
carcinoma for neuroendocrine markers is not
recommended, as there is currently no clinical relevance.
Because of the low incidence of NEC, and because there
are no data from prospective clinical trials, the optimal
management and the prognosis should be derived from
case reports or series. As future perspectives, cancer
registries to centralize uniform data collection might be
useful; moreover, prospective clinical trials are needed and
better knowledge of the molecular profile could help to
identify novel targets for a tailored treatment. The purpose
of this case report is to raise awareness on this rare type of
cancer and the lack of information regarding the prognosis
and the optimal treatment.
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